D2L Expands Footprint in Non-profit Sector
D2L adds non-profit organizations including MENTOR, Autism Ontario, and Canadian Mental Health Association
"D2L is proud to support non-profit organizations dedicated to fostering positive change in our world through the transformative force of education" said
In
Also in
In
These new partnerships add to D2L's existing list of nonprofit customers, which includes Girls Who Invest (GWI), The Rick Hansen Foundation, The Robb Nash Project, and Year Up.
Year Up is a non-profit workforce development organization dedicated to closing the Opportunity Divide by connecting young adults to top companies to help launch their careers, power business, and build community.
"Year Up is delighted to work with D2L," said
Learn more about D2L for nonprofit organizations.
D2L is transforming the way the world learns—helping learners of all ages achieve more than they dreamed possible. Working closely with clients all over the world, D2L is supporting millions of people learning online and in person. Our growing global workforce is dedicated to making the best learning products to leave the world better than they found it. Learn more about D2L for K-12, higher education and businesses at www.D2L.com.
X: @D2L
© 2024 D2L Corporation.
The D2L family of companies includes D2L Inc., D2L Corporation, D2L Ltd, D2L Australia Pty Ltd, D2L Europe Ltd, D2L EU B.V., D2L Asia Pte Ltd and D2L Brasil Soluções de Tecnologia para Educação Ltda.
All D2L marks are trademarks of D2L Corporation. Please visit D2L.com/trademarks for a list of D2L marks. All other trademarks are the property of their respective owners.
View original content to download multimedia:https://www.prnewswire.com/news-releases/d2l-expands-footprint-in-non-profit-sector-302097848.html
SOURCE D2L
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deloitte: Back-to-School Spending Holds Steady During Economic Uncertainty
- Apertura Gene Therapy Announces Cooperative Research and Development Agreement with Institutes of the NIH to Test Investigational Gene Therapy for Niemann-Pick Disease Type C1
- Trumid Reports June and Q2 2026 Trading Highlights
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share